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ABSTRACT 
 
Introduction: The National Institutes of Health Stroke Scale (NIHSS) and 
Scandinavian Stroke Scale (SSS) are both validated measures of neurological 
impairment and have been used in many acute stroke trials. Methods for 
interconverting SSS and NIHSS are needed. 
 
Methods: Conversion equations were developed using linear regression (both 
unadjusted, and adjusted for age and sex) using a random 50% of the data at both 
baseline and 90 days. The remaining 50% of data were used to test the accuracy of 
the models produced.  
 
Results: Data from 5 acute stroke trials (2,004 patients) were included. Fitted models 
at baseline were NIHSS=25.68–0.43xSSS (R2=0.57, prediction error (PE) -0.2, 
p=0.20), and SSS=50.37–1.63xNIHSS (R2=0.59, PE 0.2, p=0.35). 90 day models 
were NIHSS=22.99-0.39xSSS (R2=0.82, PE -0.3, p=0.001), and SSS=56.68–
2.20xNIHSS (R2=0.80, PE -0.4, p=0.08). Adjustment did not materially improve the 
R2 values.  
 
Conclusion: Total scores for NIHSS and SSS may be interconverted with good 
precision; the mathematical conversion equations may prove useful in clinical practice 
and in comparison of data from observational studies and randomised trials. 
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INTRODUCTION 
Stroke severity is measured routinely, using an impairment scale, in acute stroke 
trials. Common scales include the National Institutes of Health Stroke Scale 
(NIHSS)(1) and Scandinavian Stroke Scale (SSS)(2). Both scales are validated and 
share common measures of impairment, but differ in their direction of measurement 
(e.g. no impairment is 0 of 42 in NIHSS and 58 of 58 in the SSS), the weighting they 
give to individual items, and the inclusion/exclusion of specific measures (e.g. SSS 
records hand strength, NIHSS measures extinction but not vice versa). As a result, it 
is not possible to derive one score directly from the other. Nevertheless, the scales 
are highly interdependent so interconversion is possible and meaningful. In the past, 
conversion schemes have been developed for various stroke impairment scales;(3,4) 
a scheme for converting NIHSS and SSS was recently published based on just 144 
patients.(5)  
 
The aim of the study was to develop reliable mathematical models for interconversion 
using a large dataset from the Virtual International Stroke Trials Archive (VISTA).(6) 
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METHODS 
Data 
Data from five acute stroke trials included in VISTA (6), where both NIHSS and SSS 
had been recorded at baseline and day 90, were included. Information on age, sex, 
side of stroke, t-PA use, stroke type, and functional outcome at 90 days (modified 
Rankin Scale and Barthel Index) were also provided. 
 
Statistical methods 
Conversion equations were developed using linear regression (both unadjusted, and 
adjusted for age and sex) using 50% of the data selected at random; the remaining 
50% of data were used to test the accuracy of the models produced. The trials all 
excluded patients with mild impairment (e.g. NIHSS<3, SSS>50) and used exclusion 
criteria that will have confounded impairment, e.g. time to treatment, age and sex. In 
addition, we excluded data from the severe extreme of the NIHSS, where data were 
sparse (NIHSS>37); no such exclusion was needed for the SSS as data was well 
populated along the scale. The difference between the actual and predicted values 
were calculated for both equations and the t-test was used to see if this difference 
was significantly different to zero.(4) The test data set was also used to compare the 
baseline NIHSS to SSS model with one produced in a previous paper.(5)  All statistical 
analyses were carried out using SAS (version 9) and statistical significance relates to 
p<0.05. 
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RESULTS 
Data from five completed acute stroke trials were included, with a mean time to 
treatment of 7 hours. 2,004 patients had baseline data collected on both the SSS and 
NIHSS.  1,628 patients had day 90 data available for both scales, and 1,505 patients 
had both baseline and day 90 data. The patients included are reasonably 
representative of stroke trial patients, with a mean age of 66 (standard deviation 
11.8) and slightly more males (57%) than females. 
 
Conversion models 
The conversion models are shown in table 1. The day 90 models had greater adjusted 
R2 values than the baseline models (R2 0.57 to 0.60 at baseline and 0.80 to 0.82 at 
day 90) and therefore have a better fit and explain more of the variation. Further, 
adjusting for age and sex did not substantially change the fit of the models. When 
comparing the actual values to the predicted values, all models, apart from the NIHSS 
to SSS conversion at day 90, showed a non-significant difference between the actual 
data and that produced by the models. The NIHSS to SSS day 90 model tended to 
over predict the NIHSS by a mean of 0.29 points (0.73 for the adjusted model). 
 
When comparing the baseline NIHSS->SSS conversion model with the model 
produced by Ali et al (SSS=50-2*NIHSS)(5), the conversion model given here 
(SSS=50.37-1.63*NIHSS) more closely predicted the actual SSS score - mean 
difference between the actual and predicted values 5.02 in the model by Ali et al and -
0.29 in the model produced here. 
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DISCUSSION 
The results show that NIHSS and SSS can be derived from each other in both 
directions with reasonable to good degrees of reliability. Mathematical models using 
data measured at baseline had an acceptable level of fit between the actual and 
predictive values. In particular, the variation was always less than one point on either 
scale. The models produced with data collected at 90 days post randomisation had a 
higher goodness of fit, although converting SSS to NIHSS predicted higher values of 
NIHSS than observed. Taking account of age and sex did not change the results or 
improve the goodness of fit of the models.  
 
Several comments can be made about this study. First, although the five included 
trials had varying inclusion-exclusion criteria, patients with mild or very severe 
impairment were excluded, so data at the extremes of the scales were sparse. 
Second, the scales work in different directions, include different weightings for some 
common items, and contain some items not present in the other. Although these 
differences could affect the validity of the developed conversion models, the data 
come from five rigorously designed and conducted trials. Furthermore, the developed 
mathematical models are based on the largest dataset and facilitate bidirectional 
translation of the two scales.(6) Last, the formulae for interconverting SSS and NIHSS 
are only given for measurements at baseline and 90 days, since these are the time 
points for the source data. Nevertheless, these time points reflect the most common 
used in clinical trials and therefore occur when interconversion of stroke scales may 
be most needed.  
 
This work may be useful to researchers in several respects. The NIHSS is routinely 
used in clinical practice and trials in the US, whilst European countries tend to use 
either scale. Hence, clinicians may wish to interconvert the scales to facilitate 
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comparisons between countries. The models may also be useful in guidelines and 
meta-analyses, allowing data from different observational studies and randomised 
trials to be integrated.  
 
In summary, the NIHSS and the SSS may be interconverted in both directions using 
mathematical equations with acceptable fit and accuracy.  
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TABLE 1 
Mathematical conversion models 
Time point Conversion Unadjusted Adjusted 
Model Adj R2 Model Adj R2 
Baseline SSS<-NIHSS SSS=50.37-1.63*NIHSS 0.59 SSS=47.33-(1.62*NIHSS)+(0.03*AGE)+(1.29*MALE) 0.60 
Day 90 SSS<-NIHSS SSS=56.68-2.20*NIHSS 0.80 SSS=62.26-(2.18*NIHSS)-(0.10*AGE)+(0.92*MALE) 0.80 
Baseline NIHSS<-SSS NIHSS=25.68-0.43*SSS 0.57 NIHSS=22.45-(0.43*SSS)+(0.04*AGE)+(0.29*MALE) 0.58 
Day 90 NIHSS<-SSS NIHSS=22.99-0.39*SSS 0.82 NIHSS=24.59-(0.39*SSS)-(0.02*AGE)+(0.28*MALE) 0.82 
 
 
 
 
 
 
 
 
